<DOC>
	<DOCNO>NCT02241720</DOCNO>
	<brief_summary>Regorafenib Second Line Single Agent Treatment Metastatic Advanced Adenocarcinoma Esophagus , Gastroesophageal Junction Stomach</brief_summary>
	<brief_title>Regorafenib Second Line Treatment Metastatic Advanced Upper GI Cancers</brief_title>
	<detailed_description />
	<criteria>Histological diagnosis metastatic locally advanced inoperable adenocarcinoma esophagus , gastroesophageal junction stomach . Patients must show sign progression le 4 month treat first line therapy metastatic locally advanced inoperable cancer . Patients must measureable disease screen Response Evaluation Criteria Solid Tumors 1.1 criterion Age great equal 18 year . Eastern Cooperative Oncology Group Performance Status 01 Subjects must able understand willing sign write informed consent form . A sign informed consent form must appropriately obtain prior conduct trialspecific procedure . All acute toxic effect prior treatment resolve National Cancer Institute Common Terminology Criteria Adverse Events version 4.0 Grade 1 less time signing Informed Consent Form . Alopecia ( grade ) peripheral neuropathy less grade 2 allow . Adequate bone marrow , liver liver function assess laboratory requirement Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign informed consent form least 3 month last dose study drug . Highly effective contraception must use ( male condom spermicidal , diaphragm spermicidal , intrauterine device ) sex . Subject must able swallow retain oral medication . Prior use regorafenib Uncontrolled hypertension ( systolic pressure great 140 mm Hg diastolic pressure great 90 mm Hg National Cancer Institute Common Terminology Criteria Adverse Events version 4.0 repeated measurement ) despite optimal medical management . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association great Class 2 . Cardiac arrhythmia require antiarrhythmic therapy beta blocker . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . Evidence history bleed diathesis coagulopathy . Any hemorrhage bleeding event great equal National Cancer Institute Common Terminology Criteria Adverse Events Grade 3 within 4 week prior start study medication . Subjects thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack ) deep vein thrombosis pulmonary embolism within 6 month start study treatment Subjects previously untreated concurrent cancer distinct primary site histology except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 3 year randomization allow . All cancer treatment must complete least 3 year prior start study treatment . Patients severe hepatic impairment ( ChildPugh Class C ) Known history human immunodeficiency virus infection current chronic active hepatitis B C infection require treatment antiviral therapy . Patients require intravenous antiviral intravenous antibiotic treatment ongoing infection Symptomatic metastatic brain meningeal tumor . Presence nonhealing wound , nonhealing skin ulcer , bone fracture . Patient 's history kidney disease persistent proteinuria must less Grade 3 proteinuria per NCI CTCAE v4.0 screening . If patient history kidney disease persistent proteinuria , urine protein test perform random urine sample . If result normal additional testing require . If result abnormal , 24 hour urine collect determine proteinuria less Grade 3 . Interstitial lung disease ongoing sign symptoms time informed consent . Pleural effusion ascites cause respiratory compromise ( great equal National Cancer Institute Common Terminology Criteria Adverse Events version 4.0 Grade 2 dyspnea ) . Patients may undergo thoracentesis paracentesis improve symptom prior enrollment . History organ allograft ( include corneal transplant ) . Known suspect grade 3 allergy hypersensitivity study drug , study drug class , excipients formulation give course trial . Any malabsorption condition opinion investigator would significantly impact drug absorption . Women pregnant breastfeeding . Any condition , investigator 's opinion , make subject unsuitable trial participation . Substance abuse , medical , psychological social condition opinion investigator may interfere subject 's participation study evaluation study result . Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , biologic therapy , tumor embolization ) within 28 day start study treatment . Palliative radiation allow . Concurrent use another investigational drug device , within 3 week start study treatment . Concurrent use strong CYP3A4 inducer ( e.g . rifampin , phenytoin , carbamazepine , phenobarbital , St. John 's Wort ) Concurrent use strong inhibitor CYP3A4 ( e.g . clarithromycin , grapefruit juice , itraconazole , ketoconazole , nefazadone , posaconazole , telithromycin , voriconazole ) Major surgical procedure , open biopsy , significant traumatic injury within 3 week start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>